Catalyst Pharmaceuticals Inc
CPRX
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.82B
Close$
$16.80
46.3% downside
Current Fair Value
46.3% downsideOvervalued by 46.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.82 Billion |
|---|---|
| Enterprise Value | $3.07 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $1.75 |
| Beta | 0.72 |
| Outstanding Shares | 122,254,171 |
Return
| Return on Equity | 21.85% |
|---|---|
| Return on Assets | 19.29% |
| Return on Invested Capital | 27.65% |
Valuation & Multiples
| P/E Ratio | 17.25 |
|---|---|
| PEG | 139.88 |
| Price to Sales | 7.82 |
| Price to Book Ratio | 3.91 |
| Enterprise Value to Revenue | 5.14 |
| Enterprise Value to EBIT | 10.93 |
| Enterprise Value to Net Income | 13 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 13, 2026
EPS Estimate
$0.40
Average shareholder expectationRevenue Estimate
$143.86 M
Average shareholder expectationNext Earnings Call
Expected Date
August 5, 2026
EPS Estimate
$0.67
Average shareholder expectationRevenue Estimate
$155.20 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.3141▲ 70.13% |
|---|---|
| Total Calls | 117,800▲ 60.05% |
| Total Puts | 154,800▲ 243.24% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 85.22%▲ 0.40% |
|---|---|
| Total Invested | $2.58B▲ 6.36% |
| Investors Holding | 387▲ 9.00% |
ESG Score
No data
About Catalyst Pharmaceuticals Inc
CEO: Patrick McEnany